FI20115914L - MODIFIED ONCOLYTIC VIRUS - Google Patents

MODIFIED ONCOLYTIC VIRUS Download PDF

Info

Publication number
FI20115914L
FI20115914L FI20115914A FI20115914A FI20115914L FI 20115914 L FI20115914 L FI 20115914L FI 20115914 A FI20115914 A FI 20115914A FI 20115914 A FI20115914 A FI 20115914A FI 20115914 L FI20115914 L FI 20115914L
Authority
FI
Finland
Prior art keywords
virus vectors
vaccinia
vaccinia virus
modified oncolytic
oncolytic virus
Prior art date
Application number
FI20115914A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI20115914A0 (en
Inventor
Akseli Hemminki
Sari Pesonen
Marko Ahonen
Markus Vaehae-Koskela
Suvi Parviainen
Vincenzo Cerullo
Iulia Diaconu
Eerika Karli
Original Assignee
Oncos Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncos Therapeutics Ltd filed Critical Oncos Therapeutics Ltd
Priority to FI20115914A priority Critical patent/FI20115914L/en
Publication of FI20115914A0 publication Critical patent/FI20115914A0/en
Priority to PCT/FI2012/050895 priority patent/WO2013038066A1/en
Publication of FI20115914L publication Critical patent/FI20115914L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C12N15/8636—Vaccina virus vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Abstract

The invention relates to modified oncolytic vaccinia virus vectors and their uses in cancer therapy. The vaccinia virus vectors comprise inactivating mutations in the thymidine kinase gene and in the vaccinia growth factor gene in addition to genes encoding marker or adjuvant proteins. A production method for the inventive vaccinia construct is also disclosed. The vaccinia virus vectors are useful for systemic and sequential therapeutic use for cancer.
FI20115914A 2011-09-16 2011-09-16 MODIFIED ONCOLYTIC VIRUS FI20115914L (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FI20115914A FI20115914L (en) 2011-09-16 2011-09-16 MODIFIED ONCOLYTIC VIRUS
PCT/FI2012/050895 WO2013038066A1 (en) 2011-09-16 2012-09-14 Modified oncolytic vaccinia virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20115914A FI20115914L (en) 2011-09-16 2011-09-16 MODIFIED ONCOLYTIC VIRUS

Publications (2)

Publication Number Publication Date
FI20115914A0 FI20115914A0 (en) 2011-09-16
FI20115914L true FI20115914L (en) 2013-03-17

Family

ID=44718819

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20115914A FI20115914L (en) 2011-09-16 2011-09-16 MODIFIED ONCOLYTIC VIRUS

Country Status (2)

Country Link
FI (1) FI20115914L (en)
WO (1) WO2013038066A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973892B2 (en) * 2012-09-04 2021-04-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
WO2015042707A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-2 fusion proteins and uses thereof
US9809803B2 (en) 2013-11-21 2017-11-07 National University Corporation Tottori University Mitogen-activated protein kinase-dependent recombinant vaccinia virus (MD-RVV) and use thereof
JP6592505B2 (en) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Interleukin-2 super antagonist, partial agonist and antagonist
KR101845739B1 (en) * 2014-10-08 2018-04-05 부산대학교 산학협력단 Novel Oncolytic Virus, Method for Preparing, and Uses thereof
BR112017018160A2 (en) 2015-02-25 2018-04-10 Memorial Sloan-Kettering Cancer Center use of inactivated non-replicating modified vaccinia ankara virus (mva) as monoimmunotherapy or in combination with solid tumor immune checkpoint blocking agents
KR20180006916A (en) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 Use of MVA or MVA delta E3L as an immunotherapeutic agent for solid tumors
KR20160140075A (en) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 Promoter derived from the poxviridae and vector including the same
EP3307330B1 (en) * 2015-06-15 2021-03-10 New York University Method of treatment using oncolytic viruses
CN109415703A (en) 2016-01-08 2019-03-01 雷普利穆内有限公司 Modified virus
MX2018010204A (en) 2016-02-25 2019-05-06 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy.
JP7034080B2 (en) 2016-02-25 2022-03-11 メモリアル スローン ケタリング キャンサー センター Recombinant MVA or MVAΔE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
JP2019528753A (en) 2016-09-21 2019-10-17 スティーブン エイチ． ソーン， High mobility group BOXI mutant
TW201819400A (en) 2016-11-02 2018-06-01 大衛 伊凡斯 Synthetic chimeric poxviruses
CA3045228C (en) * 2016-12-28 2024-01-02 Transgene Sa Oncolytic viruses and therapeutic molecules
CN111107872A (en) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 Vaccinia virus mutants useful for cancer immunotherapy
CN111201035A (en) 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Uses and methods for IL-2 superagonists, agonists, and fusions thereof
KR20220124817A (en) 2017-08-07 2022-09-14 더 리전트 오브 더 유니버시티 오브 캘리포니아 Platform for generating safe cell therapeutics
SG11202010272PA (en) * 2018-05-02 2020-11-27 David Evans Synthetic chimeric vaccinia virus
EP3849314A4 (en) * 2018-09-14 2021-12-08 Mayo Foundation for Medical Education and Research Materials and methods for treatment with oncolytic viruses and modified car t cells
CN109234238A (en) * 2018-09-30 2019-01-18 杭州华安单抗生物技术有限公司 Cell strain and its preparation method of application, the cultivating system of B cell and cultural method and antibody
US20210388388A1 (en) * 2018-10-22 2021-12-16 Icellkealex Therapeutics Llc Mutant vaccinia viruses and use thereof
MX2021013601A (en) * 2019-05-09 2021-12-10 Sator Therapeutics LLC Delivery of oncolytic viruses using dendritic cells.
CN111979204B (en) * 2019-05-24 2023-10-13 杭州功楚生物科技有限公司 Oncolytic vaccinia virus carrying sponge lectin gene, construction method and application
BR112023026235A2 (en) * 2021-06-17 2024-03-05 Kalivir Immunotherapeutics Inc TNFSF-L FUSION PROTEINS AND THEIR USES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014314A2 (en) * 2002-08-12 2004-02-19 David Kirn Methods and compositions concerning poxviruses and cancer
US20090317456A1 (en) * 2006-10-13 2009-12-24 Medigene Ag Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer

Also Published As

Publication number Publication date
FI20115914A0 (en) 2011-09-16
WO2013038066A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
FI20115914L (en) MODIFIED ONCOLYTIC VIRUS
CY1123010T1 (en) SMALL MOLECULE TRIAL GENE INCIPULATION FROM NORMAL AND TUMOR CELLS AS ANTICANCER THERAPY
CY1120103T1 (en) LENGTH CARE PRODUCER SCALE SYSTEM COMPATIBLE WITH INDUSTRIAL PHARMACEUTICAL APPLICATIONS
AU2017261625B2 (en) Non-natural consensus albumin binding domains
CY1124050T1 (en) HUMAN CD30 ANTIGEN BINDING PROTEINS
MX2018001040A (en) Artificial nucleic acid molecules.
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
MX2015012450A (en) Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system.
MX356625B (en) Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell.
HK1198538A1 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
HK1202800A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins 21
MX357803B (en) Artificial nucleic acid molecules.
CA2818990A1 (en) Designed repeat proteins binding to serum albumin
MX2016009771A (en) Methods and products for nucleic acid production and delivery.
MX2015008446A (en) Multivalent binding protein compositions.
PH12018501404A1 (en) Forms of rifaximin and uses thereof
MX346923B (en) Genes and proteins for alkanoyl-coa synthesis.
MX2015002371A (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same.
MX358706B (en) Artificial nucleic acid molecules comprising a 5'top utr.
CY1114483T1 (en) NEW REGULATORY INFORMATION
MX2014010750A (en) Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof.
BR112014006158A2 (en) binding molecule, nucleic acid molecule, vector, host cell, process for preparing a binding molecule, methods for enhancing an immune response in a human individual, for treating cancer in a human individual in need thereof, for reducing the size of a tumor or inhibit the growth of cancer cells in an individual or reduce or inhibit the development of metastatic cancer in an individual suffering from cancer, use of a binding molecule, and pharmaceutical composition
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX364922B (en) Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1.
BR112014015016A8 (en) HOMODIMERIC PROTEIN OF TWO IDENTICAL AMINO ACID CHAINS, AMINO ACID CHAIN, NUCLEIC ACID MOLECULE, PHARMACEUTICAL COMPOSITION, HOST CELL, METHOD OF PREPARATION OF A HOMODIMERIC PROTEIN, METHOD FOR PREPARING A VACCINE, VACCINE AND METHOD OF TREATMENT OR PREVENTION

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: ONCOS THERAPEUTICS LTD.

FD Application lapsed